Vanguard Personalized Indexing Management LLC Buys 628 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Vanguard Personalized Indexing Management LLC lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 8.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,186 shares of the medical research company’s stock after acquiring an additional 628 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Charles River Laboratories International were worth $1,687,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Charles River Laboratories International by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 6,046,467 shares of the medical research company’s stock worth $1,638,290,000 after acquiring an additional 66,161 shares in the last quarter. Clearbridge Investments LLC boosted its stake in Charles River Laboratories International by 3.1% during the 1st quarter. Clearbridge Investments LLC now owns 1,513,138 shares of the medical research company’s stock valued at $409,985,000 after purchasing an additional 45,079 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in Charles River Laboratories International by 11.9% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,251,618 shares of the medical research company’s stock valued at $258,559,000 after purchasing an additional 132,802 shares during the period. Meritage Group LP boosted its stake in Charles River Laboratories International by 2.3% during the 1st quarter. Meritage Group LP now owns 1,182,268 shares of the medical research company’s stock valued at $320,336,000 after purchasing an additional 26,892 shares during the period. Finally, Earnest Partners LLC boosted its stake in Charles River Laboratories International by 0.5% during the 1st quarter. Earnest Partners LLC now owns 893,761 shares of the medical research company’s stock valued at $242,165,000 after purchasing an additional 4,393 shares during the period. Institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. StockNews.com upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating in a research note on Tuesday, August 20th. TD Cowen decreased their target price on Charles River Laboratories International from $228.00 to $203.00 and set a “hold” rating for the company in a research note on Monday, August 12th. UBS Group decreased their target price on Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating for the company in a research note on Thursday, August 8th. Baird R W downgraded Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 8th. Finally, JPMorgan Chase & Co. downgraded Charles River Laboratories International from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $270.00 to $205.00 in a research report on Thursday, August 8th. Ten equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $230.93.

Charles River Laboratories International Trading Down 1.8 %

Shares of CRL opened at $205.79 on Friday. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00. The company has a current ratio of 1.58, a quick ratio of 1.21 and a debt-to-equity ratio of 0.65. The stock has a 50 day simple moving average of $209.34 and a 200-day simple moving average of $223.80. The stock has a market cap of $10.60 billion, a PE ratio of 24.21, a PEG ratio of 3.89 and a beta of 1.36.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.39 by $0.41. Charles River Laboratories International had a return on equity of 14.96% and a net margin of 10.83%. The business had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.03 billion. On average, sell-side analysts predict that Charles River Laboratories International, Inc. will post 10.01 EPS for the current fiscal year.

Charles River Laboratories International announced that its board has authorized a share buyback plan on Wednesday, August 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to repurchase up to 9.6% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).